| ROCHE GS | 270.25 / -0.22% |
| Date/Time | 03/21 / 16:52 |
| Chg. / Chg.(%) | -0.60 / -0.22% |
| Bid | 270.20 / 168 |
| Ask | 270.25 / 2045 |
| Open | 269.70 |
| Previous Close | 270.85 |
| High | 270.70 |
| Low | 267.70 |
| Volume [CHF] | 163,117,555.45 |
| Volume [Units] | 752,194 |
| Price fixings | 8249 |
| ISIN | CH0012032048 |
| Security | ROG |
| Exchange | SIX Swiss Exchange |
| Type | Stock |
| Exchange | Last | Volume | |
|---|---|---|---|
| SIX Swiss Ex.. | 270.25 |  |
752,194 |
| Cboe Europe .. | 270.25 | |
78,979 |
| Turquoise | 270.20 | |
64,754 |
| London Inter.. | 270.20 | |
40,350 |
| Xetra | 239.40 | |
2,711 |
| Frankfurt | 238.450 | |
1,900 |
| TradeGate | 239.500 | |
747 |
| Stuttgart | 239.350 | |
440 |
| Nasdaq Other.. | 270.5000 |  |
90 |
| Borsa Italia.. | 238.00 | |
50 |
| Düsseldorf | 238.45 | |
5 |
| Berlin | 239.30 | |
0 |
| München | 238.60 | |
0 |
| Hamburg | 238.50 | |
0 |
| Lang & Schwa.. | 239.517 | |
|
| gettex | 239.750 | |
|
| Mexico | 5,220.00 | 256 | |
| Mexico | 4,744.44 | 32 | |
| Borsa Italia.. | 239.70 | ||
| EUREX | Options | ||
News
- Biopharmaceuticals Market Analysis & Outlook, 2019 to 2024 - Their Ability to Treat Previously Untreatable Diseases is Spurring Growth
03/20/2019 / 12:40 - GlobeNewswire - FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
03/19/2019 / 07:00 - GlobeNewswire - European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease
03/15/2019 / 07:00 - GlobeNewswire - European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors
03/14/2019 / 07:00 - GlobeNewswire - Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
03/11/2019 / 07:03 - GlobeNewswire
Real-time